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This review focuses on the development, current techniques, and clinical use of continuous
intravascular blood gas monitoring (CIBM) devices in anaesthesia and intensive care. The oper-
ating principles, range of application, performance, limitations, costs, and impact on patient
treatment and outcome, are discussed. Studies of early and currently available CIBM devices
were analysed. At present, the Paratrend 7+â (PT7+â) for adults and NeotrendÔ (NTÔ) for
newborns are the only commercially available CIBM systems. The PT7+â contains three optical
sensors to measure PO2, PCO2 and pH, as well as a thermocouple to measure temperature.
The NTÔ is a modi®cation of the PT7+â to continuously monitor PO2, PCO2, pH and tempera-
ture in newborns. Under laboratory conditions, good performance over a wide range of blood
gas values was observed with the Paratrend 7â (PT7â). Performance in the clinical setting was
not as satisfactory, especially for PO2 values. However, the performance and accuracy of CIBM
devices appear to be suf®cient for clinical use and they are being used clinically in selected
patient groups. Several factors affecting the performance of CIBM are considered.
Br J Anaesth 2003: 91; 397±407
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continuous intravascular blood gas
Arterial blood gas analyses are essential to monitor gas
exchange in critically ill patients and during anaesthesia for
major surgery. Usually, arterial blood samples are drawn
intermittently and analysed in a central laboratory or by a
point-of-care blood gas analyser. Several problems associ-
ated with intermittent sampling have been described:
indications for sampling are vague; analyses are often
performed only after adverse events; sample transportation
and analyses may be problematic; a therapeutic response
can only be made after a delay; and there is a risk of blood
loss and infection.5 15 26 39 60
Pulse oximetry, capnometry and transcutaneous blood
gas measurement have been used for many years to assess
gas exchange continuously and non-invasively. However,
these non-invasive methods cannot fully replace arterial PO2
(PaO2), arterial PCO2 (PaCO2), and arterial pH (pHa) analyses
in the clinical setting because of their signi®cant limita-
tions.16 54 83 Oxygen saturation assessed by pulse oximetry
(SpO2), or intravascular arterial oxygen saturation (SaO2)
sensors cannot detect a high PaO2, and de®nition of a safe
lower saturation limit is dif®cult.61 70 72 Moreover, pulse
oximetry may display erroneous readings in the presence of
dyshaemoglobinaemia, dyes (e.g. methylene blue, indigo
carmine, indocyanine green), ambient light, low peripheral
perfusion, motion artefacts, and other technical prob-
lems.4 79 Measuring end-tidal CO2 concentration by capno-
metry only provides an accurate estimation of PaCO2 in
intubated patients with normal pulmonary function, a
normal ventilation±perfusion ratio of the lungs, and normal
haemodynamics. However, critically ill patients do have
varying pulmonary and cardiovascular derangements, lead-
ing to unreliable end-tidal CO2 values. Transcutaneous
monitoring of PO2 and PCO2 is known to be accurate in
small children, but many factors affect this technology in
adults, including patient characteristics (variation in skin
thickness, oedema, tissue hypoperfusion, administration of
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vasoconstrictor agents), or technical problems (trapped air
bubbles, improper placement, damaged membranes,
inappropriate calibration, and frequent recalibration).9 55
During the past decade, marked advances in continuous
intravascular blood gas monitoring (CIBM) have been
achieved by miniaturization of the sensors measuring PO2,
PCO2 and pH. CIBM appears to be desirable at least in
selected patient groups, provided the technique proves to be
reliable and cost-effective.
Methods
The literature on CIBM in anaesthesia and intensive care
was retrieved using `Medline' searches (PubMed, National
Library of Medicine). The following terms alone and in
combination were used: continuous, arterial, intra-arterial,
intravascular, blood gas, monitoring, measurement, device,
sensor, paratrend, and neotrend. Laboratory and clinical
evaluation studies, review articles and studies on risk±
bene®t, costs and outcome of CIBM were selected. The
reference lists of retrieved articles were further studied to
complete the search on the topic of this review.
Furthermore, manufacturers' instructions were obtained to
describe the technology of the currently available commer-
cial CIBM devices.
Statistics
Inconsistencies in the statistical analysis of comparisons
between different measurement methods have been ad-
dressed by Mantha and colleagues.41 When assessing new
technology, the use of adequate statistical methods and
standard nomenclature are essential to draw valid conclu-
sions.
To evaluate a new blood gas measuring device, for
example a CIBM device, it should be compared with an
established one, such as a laboratory blood gas analyser.
Agreement between the two measurement techniques is best
described by Bland and Altman analysis.6±8 The mean
difference between values obtained from the new and the
established measurement technique is the estimated bias.
Measures of dispersion of this difference represent the
random error inherent in either or both devices. It is termed
precision in some studies. However, precision is a measure
of repeatability. In the past, the term precision was often
incorrectly de®ned and was used in the wrong context. It
was therefore suggested that this term should be avoided in
measurement comparison studies.41 Instead, upper limit of
agreement (ULA) as bias +2 SD and lower limit of
agreement (LLA) as bias ±2 SD should be used. Bias 6 2
SD/limits of agreement are only estimates of the values that
apply to all the population measured. To know how precise
the estimates are, one should also report the con®dence
intervals (CI). Unfortunately, the correct statistical method
has only been applied in a few studies on CIBM.
Development of CIBM
Technology and history
The principles, technology and history of CIBM have been
described in detail in previous reviews.39 57 67 78 80 PO2,
PCO2 and pH can be measured by electrochemical and
photochemical/optical sensors (Table 1). If both technolo-
gies are combined, it is called a hybrid probe.
Electrochemical sensors
Electrochemical sensors have been used for intravascular
PO2 measurement. The principle is a modi®ed Clark
electrode.10 A small polarizing potential is maintained
between the platinum cathode and the silver anode. The
electrodes are immersed in an electrolyte solution sur-
rounded by an oxygen-permeable membrane. Oxygen
diffuses into the chamber, and is reduced at the platinum
cathode, producing a current proportional to PO2.
Photochemical/optical sensors: optodes
Sample chambers containing dyes are illuminated with light
of a speci®c wavelength via optical ®bres. The illuminating
light will be variably transmitted, re¯ected, absorbed and re-
emitted depending on the concentration of oxygen, carbon
dioxide and hydrogen ions. The photochemical changes of
the illuminating light will be used to calculate PO2, PCO2
and pH values.
Early multiparameter CIBM devices
Extensive research was done before commercialization of
CIBM technology. Single parameter CIBM devices to
measure PO2 electrochemically were developed within a
short time of Clark introducing his electrode in 1956.3 10
Within a decade, Lubbers and Opitz published work on a
CIBM probe with optodes to measure PO2 and PCO2.
36 50
Some years later in 1986, the same group described a
multiparameter CIBM probe to assess PO2, PCO2 and pH
optically, and to measure temperature by a thermocouple.21
These devices preceded the early multiparameter CIBM
devices (Table 2).
Table 1 Comparison of optical and electrochemical sensor technology
Optodes Electrodes
Miniaturization Easy Dif®cult
Measurement technique Light Electrochemical
Interference Ambient light Radio frequency emissions
Chemistry of sensor Change with time,
bleaching
Unchanged
Reference electrode No Yes
Response time Limited by membrane Limited by membrane
Stability over time High, minimal drifts Lower, drifts with time
Costs Expensive Less expensive
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The CDIÔ 1000 Blood Gas Monitoring System (CDI-3M
Healthcare, Tustin, CA, USA; Table 2) consisted of
¯uorescent PO2, PCO2 and pH sensors and a thermocouple.
In vitro and in vivo animal studies by Miller and
colleagues,44 and Shapiro and colleagues64 showed excel-
lent results. High fragility and poor results in clinical
studies, especially for PO2, attributable to adherence to
blood vessel walls (wall effect), rendered the commercial
production and wider use of the system impossible.2 39 40
Smith, King and Schlain,66 and Zimmerman and
Dellinger84 studied another CIBM device, the Optex
Biosentryâ System (Optex Biomedical, The Woodlands,
TX, USA; Table 2). Absorbance sensors were used for pH
and PCO2, and a ¯uorescent sensor was used for PO2
assessment. Flexible optical ®bres allowed the indicator dye
chamber to be located at the side of the probe, rather than at
the tip, thus decreasing the wall effect problem. No further
investigations or progress in marketing were made partly
because of high costs and also because of poor accuracy of
the probe in some studies.39
The PB 3300 (Puritan Bennett Corp., FoxS Division,
Carlsbad, CA, USA; Table 2) was a different CIBM device
which consisted entirely of ¯uorescent sensors. It was
evaluated in laboratory, animal, and clinical studies
(Table 2). Some improvements were made with this device
by enabling circumferential sensing of gases which was
associated with a reduced wall effect. The system has been
withdrawn for economical reasons as a result of high costs
and poor performance in some clinical investigations.39 56
Current state of continuous intravascular
blood gas monitoring
Paratrend 7+â
At present, the Paratrend 7+â (PT7+â; Diametrics Medical
Inc., High Wycombe, UK; distributed by Philips Medical
Systems), and NeotrendÔ (NTÔ) are the only commer-
cially available multiparameter CIBM systems (Table 3).
Clutton-Brock, Hendry and Fink12 described the technology
of the Paratrend 7â (PT7â) in 1992. Originally, the PT7â
was a hybrid probe incorporating four different sensors: a
miniaturized Clark electrode to measure PO2; optodes to
determine PCO2 and pH (absorbance sensors, phenol red in
bicarbonate solution); and a thermocouple (copper, con-
stantan) to measure temperature and allow temperature
correction of the blood gas values. The sensors were housed
in a heparin-coated microporous polyethylene tube that was
permeable to the analytes to be measured. In 1999, the
manufacturer modi®ed the design of the PT7â and intro-
duced a new probe, the PT7+â. The Clark electrode was
replaced by an optical PO2-sensor (¯uorescent quenching
sensor, ruthenium dye in silicone matrix). The other sensors
and the main characteristics of the probe remained un-
changed. According to the manufacturer, the new PO2T
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sensor measures PO2 more precisely, with a faster response
time and less artefacts. Unfortunately, most evaluation
studies published thus far have been of the PT7â; only one
study by Menzel and colleagues43 has evaluated the new
PT7+â probe (Table 3).
NeotrendÔ
NeotrendÔ (NTÔ; Diametrics Medical Inc., High
Wycombe, UK; distributed by Philips Medical Systems), a
modi®cation of the PT7+â, was designed for CIBM in the
umbilical artery of newborn infants. As in the PT7+â, PO2,
PCO2 and pH are measured by ®breoptic sensors and the
temperature is determined by a thermocouple (Table 3).
Current clinical use
Site of measurement
The most common site for CIBM measurement is the radial
artery in adults and the femoral artery in children, particu-
larly if they are <5 yr old. There are some disadvantages of
the radial approach: it is more susceptible to motion and
positional artefacts, vasospasm, and changes in peripheral
blood ¯ow. Nevertheless, this approach is chosen routinely
in adults and older children, because of easy access, the
double blood vessel supply of the hand, and low compli-
cation rates.75 82 The umbilical artery is used for probe
insertion in neonates.46 The incidence of catheter-related
complications with the NTÔ is low and does not differ from
that observed with a standard umbilical artery catheter.13
Other sites of measurement are peripheral veins in chil-
dren,68 69 the jugular venous bulb in adults,18 and carotid
arteries, chorionic arteries and jugular veins in animal
studies.11 17
Evaluation studies of current CIBM devices, and
ranges of application
All the evaluation studies published with currently available
commercial CIBM devices are listed in Table 3. CIBM has
been applied in various clinical settings in the operating
room and the intensive care unit, as well as in experimental
studies (Table 4). Different study designs and different
statistical analyses render comparison of these studies
dif®cult. Moreover, there are methodological limitations.
For example, several studies corrected a perceived bias
during the study period by adjusting the original calibration
curve using in vitro laboratory blood gas determinations
(`recalibration'). This may be necessary after prolonged
monitoring in the clinical setting, according to the recom-
mendations of the manufacturer. However, the issue of
`recalibration' was not mentioned in all of the studies, and
`recalibration' was performed at different time points.
Similarly, the temperature at which PO2, PCO2 and pH
were measured and compared was not mentioned in all the
studies. Most authors did not address the issue of tempera-
ture correction (i.e. the use of alpha-stat or pH-stat).
Furthermore, the number of measurements per patient
varied in all the studies. Some performed a large number,
others only a few measurements with a single probe or
patient.
An animal study with the PT7â showed good perform-
ance (Table 3) over a wide range of blood gas values under
laboratory conditions.11 Another study on animals with an
NTÔ probe presented the feasibility and accuracy of
®breoptic multiparameter sensing in fetal monitoring. The
NTÔ probe showed good performance at low PO2 levels
(PO2 <6.7 kPa; bias (2 SD): ±0.2 (1.5) kPa). However, as a
result of movement and interference by the endoscopic
light, readings for all variables were only available for about
50% of the operating time. The authors concluded that
extensive modi®cation of the sensor design would be
necessary before the sensor could be used routinely in this
area.17
There are several clinical evaluation studies from the
operating theatre and the intensive care unit. Most studies in
the operating room are in adults undergoing one lung
ventilation for major thoracic surgery (thoracoscopic sur-
gery, lung transplantation),47 83 85 or major thoracoabdom-
inal surgery (oesophagectomy).29 Studies in cardiac and/or
vascular surgery,18 27 48 76 major orthopaedic surgery,79
Table 4 Applications of CIBM. OLV=one lung ventilation, LVRS=lung volume reduction surgery
Operating room Intensive care unit
Adults Thoracic surgery with OLV
Lung transplantation33 47
Major thoracoscopic surgery (e.g. LVRS)83 85 86
Critically ill patients, requiring repeated blood gas
measurements for at least 48±72 h
Cardiac, vascular surgery18 33 48 76
Liver transplantation33
Major surgery in critically ill patients33
Paediatrics High risk surgery, especially cardiac surgery27 Premature infants with congenital heart disease,
respiratory distress, reactive pulmonary vascular
resistance, and persistent fetal circulation28
Critically ill patients, requiring repeated blood gas
measurements for at least 48±72 h
Obstetrics Fetal monitoring during fetal surgery17 30 37
Animals Experimental studies
Ganter and Zollinger
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laparoscopic surgery,35 and neurosurgery43 have also been
done. Blood gas values were measured over wide ranges
(PO2 3.5±83.3 kPa, PCO2 1.8±15.2 kPa, pH 6.99±7.66).
Overall performance in PO2 measurement was relatively
poor (bias ±2.9 to 0.8 kPa, 2 SD of bias 0.5±14.4 kPa).
However, looking at the clinically important lower range of
PO2, much better results were obtained. Zaugg and
colleagues83 found a bias (2 SD) of ±0.5 (2.2) kPa for PO2
<13.3 kPa in patients undergoing thoracoscopic surgery;
Nunomiya and colleagues49 showed a bias (2 SD) of ±0.3
(1.7) kPa for PO2 <13.3 kPa; Coule and colleagues
14
measured a bias (2 SD) of 0.24 (2.18) kPa for PO2 <8.0 kPa
in children in the intensive care unit (in this article the term
precision was used and assumed to be 1 SD of the bias);
Weiss and colleagues82 obtained a bias (2 SD) of 0.1 (2.5)
kPa for PO2 <9.3 kPa in children in the intensive care unit;
and Hatherill and colleagues27 presented a bias (2 SD) of 0.0
(0.8) kPa for PO2 values ranging from 2.5 to 8.2 kPa (mean
5.3 kPa) in children with cyanotic heart disease. These
results are comparable with the animal study by Devlieger
and colleagues.17 Performance of PCO2 and pH measure-
ment was acceptable over the whole ranges.
Studies in the intensive care unit were done in
adults,1 12 49 75 77 as well as in children and neo-
nates.14 27 46 68 69 81 82 Despite poor reporting, the ranges of
measured blood gas values were smaller compared with the
operating theatre studies, despite the probes being used over
a much longer time period. The reported mean longest
duration of use was 127 h (5.3 days),81 and the single
longest duration of use was 429 h (17.8 days).46
Furthermore, the number of measurements per patient or
probe, respectively, was much greater in the intensive care
unit (17 measurements per patient or probe in the intensive
care unit vs six in the operating room), and `recalibrations'
were done more frequently in the intensive care unit.
Two studies reported on the PT7â sensors inserted in a
peripheral vein in paediatric patients.68 69 Only the values
for i.v. PCO2 and pH were compared with the respective
arterial values.
Reliability, accuracy and consistency
In the technical speci®cation sheet of the PT7+â and the
NTÔ, the manufacturer presents promising in vitro data
with blood gases and temperature measured over wide
ranges (PO2 2.6±66.6 kPa, PCO2 1.3±10.6 kPa, pH 6.80±
7.80, temperature 10±42°C) with a good performance.
Using gas-tonometered solutions, 95% con®dence limits
were: 65% or 60.4 kPa (whichever is greater) of the actual
values for a PO2 <16 kPa, and 610% for a PO2 >16 kPa;
60.4 kPa for PCO2; 60.03 for pH; and 60.3°C for
temperature. At 37°C, it took <15 s for the sensor to start
responding to a change in blood gases, and the 90%
response time for the sensor was 180 s or less. Drifts of the
sensors were <0.5% h±1 for PO2 and PCO2, and <0.005 pH
units h±1.1
Comparison of blood gas variables from continuous
intravascular sensors with those from laboratory blood gas
analysers is a controversial issue. Blood gas variables vary
substantially within short periods of time even in stable
patients in the intensive care unit. The accuracy of
laboratory blood gas analysers can be quanti®ed in the
laboratory where the values to be measured are known.
However, this is not the case in clinical studies. Thus, the
clinical performance of an optode-based intravascular probe
must be judged in comparison with an electrode-based
blood gas analyser, for which clinical performance cannot
be speci®cally quanti®ed.62 Moreover, resulting values for
bias (2 SD) of a CIBM device not only re¯ect the accuracy of
the intravascular device, but also depend on the accuracy of
the laboratory blood gas analyser used as a reference.
Laboratory blood gas analysers (even between individual
analysers of the same manufacturer), also have inconsist-
encies.24 25 The bias of intravascular sensors could either be
reduced or increased if the blood gas analysers also showed
high levels of bias. Poor repeatability [bias (2 SD)] of
variables obtained by the blood gas analyser would, in
contrast, inherently result in poorer repeatability for the
variables from the intravascular sensors.11 Blood gas values
measured by a laboratory blood gas analyser may also be
affected by pre-analytic sample errors. Therefore, even with
an ideal laboratory blood gas analyser, the measured blood
gas values would never completely re¯ect the real blood gas
values in vivo. Since intermittently drawn blood samples
analysed by laboratory blood gas analysers are the clinical
standard of care, all authors used this procedure as a
reference method to assess the accuracy of CIBM.
No of®cial recommendations concerning performance of
continuous intravascular blood gas devices exist. However,
several guidelines for laboratory blood gas analysers have
been published by the Clinical Laboratory Improvement
Amendment/Health Care Finance Administration (CLIA/
HCFA), the College of American Pathologists (CAP), and
the Emergency Care Research Institute (ECRI) (Table 5). If
they are applied to the published evaluation studies of PT7â
and NTÔ (Table 3), most of the bias values lie within these
recommended ranges. Concerning repeatability, the situ-
ation is less clear as a result of poor reporting of the
distribution of the measured PO2, PCO2 and pH values. PO2
measurements met the recommendations least, although a
much better performance was obtained in the clinically
important lower PO2 range as discussed above. In contrast,
values for PCO2 and pH were more acceptable and
comparable to the given recommendations.
As temperature in the radial artery re¯ects an intermedi-
ate or even peripheral temperature, it is not surprising that
values for temperature with the PT7â were lower (bias ±
0.5°C) than those recorded rectally.85
On the screen of CIBM devices, additional values such as
oxygen saturation, bicarbonate concentration, and base
excess are provided, which are continuously calculated
based on algorithms and normograms. These variables
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agreed poorly with those calculated by laboratory blood gas
analysers in a number of studies.18 27 85 This may re¯ect
differences in the built in algorithms.73 Interestingly, the
poor agreement between two different blood gas analysers
for bicarbonate and base excess was similar.22 Such
variations between laboratory blood gas analysers render
estimation of the accuracy of these calculated values
impossible.
Response times were analysed and found to correlate well
with the values in the manufacturer's ®gures for the PT7â.
Mean 90% in vitro response time was 70 s for PO2, 143 s for
PCO2 and 78 s for pH.
77 Response times in vivo were
comparable, as shown in clinical studies. The PT7â was also
evaluated during cemented total hip replacement. As a result
of the instantaneous effect of acetabular and femoral
cementation, mean PaO2 values dropped signi®cantly within
90 s (mean onset time) following the application.79
Furthermore, response times from four sensors were inves-
tigated after using them in patients undergoing cardiopul-
monary bypass. The mean 90% post-in vivo response time
was 100 s for PO2, 122 s for PCO2, and 123 s for pH,
respectively. Additionally, these sensors were exposed to
known concentrations of en¯urane, iso¯urane and ha-
lothane. There was no interference with the pH and PCO2
sensors by any of the anaesthetic gases tested, but halothane
interfered with PO2 measurement.
76 Other investigations
exposed PT7â sensors to the ¯uorescent drug propofol as
well as to bone cement (methyl methacrylate), and sterile
polymer powder in vitro. No interference of these sub-
stances with blood gas measurement was found.77 79
Halothane interference with PO2 measurement in the
PT7â probe was attributable to the electrochemical reduc-
tion of halothane by the Clark electrode used on the PT7â
probe. None of the anaesthetic agents have any effect on the
optical measurement of PO2, and so the PT7+
â probe should
be free from this interference.
Sensor drifts in vivo were reported in an early animal
study. Mean variation of the bias per hour was acceptable at
±0.59% for PO2, 0.42% for PCO2 and ±0.002 pH units,
respectively.11 These results were con®rmed in humans
undergoing cardiopulmonary bypass (i.e. mean variation of
the bias per hour was ±0.43% for PO2, 0.62% for PCO2 and
0.001 pH units).76
Limitations and complications
Reliable intravascular blood gas measurement depends on a
number of mechanical, electrical and physicochemical
properties of the CIBM probe as well as the conditions of
the vessel into which the probe is inserted. Blood ¯ow in the
vessel containing the probe is most critical. CIBM becomes
unreliable if blood ¯ow decreases or stops, for example
during in¯ation of a sphygmomanometer cuff, because of
vasospasm, or during cardiopulmonary resuscitation. PO2
was shown to be the most ¯ow-dependent variable. Insertion
of the probe into a femoral artery yields more reliable results
compared with those from the radial artery during low ¯ow
states.74 75 If the sensor becomes attached to the wall of the
vessel, thus measuring a combined blood and tissue PO2, the
oxygen value may be falsely low. Hybrid probes (PT7â) are
less susceptible, as the PO2 electrode has a larger surface
area. Arterial catheters are ¯ushed in vivo with a continuous
solution. If the sensing probe is not inserted for an adequate
distance over the tip of the arterial catheter, it may measure
the blood gas variables in the ¯ush solution, resulting in
errors known as the `¯ush effect'.78 Interference from
electrocautery and ambient or endoscopic light may be
another source of erroneous blood gas values.17 82 Damping
of the arterial pressure tracing or dif®culty in withdrawing
blood from the arterial catheter was reported in one study,
and occurred after an average of 35.4 h of measurement in
only four patients (15%).1 However, even without an
indwelling CIBM probe, the incidence of damping or
dif®culty in withdrawing blood from radial artery catheters
was reported to be 17±26%.58 Without any adverse events,
clot formation (incidence 8±30%) was observed in three
studies.29 68 82 Poor robustness of the ®breoptic cables led to
bending and kinking in up to 20% of patients, resulting in
probe malfunctioning and a short user life.1 27 68 82 Finally,
before measurement, a 30 min warm-up time is mandatory
for calibration. Hence, the device is not immediately
available. The unit is also quite bulky.
Table 5 Quality recommendations for laboratory blood gas analysers. ULA=upper limit of agreement, LLA=lower limit of agreement, CLIA/HCFA=Clinical
Laboratory Improvement Amendment/Health Care Finance Administration, CAP=College of American Pathologists; ECRI=Emergency Care Research Institute
PO2 PCO2 pH
Bias
Shapiro et al.65 0.7 kPa 0.4 kPa 0.05
ULA, LLA (bias 6 2 SD)
CLIA/HCFA1 42 63 65 6 3 SDa 6 1.3 kPa or 6 16%b 6 0.08
CAP63 65 6 15% 6 0.8 kPa 6 0.06
ECRI19 4.0±20.0 kPa: 6 7.5% or 6 0.6 kPab 2.7±10.7 kPa: 6 7.5% or 6 0.6 kPab c
>20.0 kPa: 6 12.5% >10.7 kPa: 6 12.5% c
a
SD of a pro®ciency blood gas analyser used as reference; bwhichever is greater; cthere is no reference method for pH measurement for laboratory
blood gas analysers.
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Costs
Costs are important, and new monitoring devices are
warranted only if cost effectiveness may be shown. Either
reduction in overall cost or an improvement in patient
outcome is required. Some cost±bene®t analyses on CIBM
have been done, but different results have been obtained.
Some authors recommended the use of CIBM and presented
cost-savings,20 82 others argued against this technology
because of high costs and low bene®ts (i.e. the monitoring
system far exceeding the clinical needs).28 This may be
attributable to a differing basis for the analyses. Costs
assumed for one conventional, intermittent laboratory blood
gas analysis varied between 2.50 and 80.00 euros per
sample. Some investigations assessed only the direct costs
of CIBM, in other words, approximately 20 000 euros for
the satellite monitor including a patient data module, 15 000
euros for the calibration unit, and 500 euros for each one
way sensor. Others also took indirect costs into account, for
example administrative costs, laboratory support, and
specialized personnel. Therefore, no concluding data are
currently available on the cost±bene®t ratio of CIBM.
Outcome
The impact of undetected changes in arterial blood gases on
patient outcome has not yet been investigated. Experimental
studies reported myocardial ischaemia with a potential risk
of myocardial damage even when the period of hypoxia was
short, if coronary blood ¯ow was limited.59 PaO2 <8.0 kPa,
as often observed during thoracic surgery with one lung
ventilation, is thought to be the threshold that should be
detected. It is associated with an increased risk of
perioperative myocardial ischaemia in susceptible individ-
uals.45 83
Although CIBM appears to be advantageous, there are no
prospective, randomized, double-blind studies of its impact
on morbidity and mortality, length of intensive care unit and
hospital stay, or myocardial and cerebral ischaemia. Future
outcome studies should focus on well-de®ned groups of
selected patients who might bene®t from CIBM (e.g.
critically ill patients with potentially rapid and unexpected
changes in blood gas values). Nevertheless, it may be
dif®cult, if not impossible, to show a positive impact of
CIBM on patient outcome.
Conclusions
Development of CIBM devices has resulted in the com-
mercially available PT7+â probe for adults and NTÔ probe
for newborns. Changes in blood gas values may be
immediately and reliably detected in the clinical setting
without signi®cant side-effects or complications.
Indications for CIBM, in terms of evidence-based medicine,
are still lacking since the cost±bene®t ratio and the impact
on patient outcome are unknown. Nevertheless, CIBM is
being used by clinicians in selected patient groups in the
operating theatre and the intensive care unit. It is useful
during surgery where blood gas values can change rapidly
and unexpectedly, for example during thoracic surgery with
one lung ventilation, cardiovascular surgery and organ
transplantation. CIBM is useful in critically ill patients
needing a considerable number of blood gas determinations
over a long period, for example premature infants with
severe cardiopulmonary disease, and patients with acute
respiratory distress syndrome, sepsis, and severe trauma.
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